Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 9/2013

01.09.2013 | Attention-Deficit Disorder (R Bussing, Section Editor)

Globalization and Cognitive Enhancement: Emerging Social and Ethical Challenges for ADHD Clinicians

verfasst von: Ilina Singh, Angela M. Filipe, Imre Bard, Meredith Bergey, Lauren Baker

Erschienen in: Current Psychiatry Reports | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Globalization of ADHD and the rise of cognitive enhancement have raised fresh concerns about the validity of ADHD diagnosis and the ethics of stimulant drug treatment. We review the literature on these two emerging phenomena, with a focus on the corresponding social, scientific and ethical debates over the universality of ADHD and the use of stimulant drug treatments in a global population of children and adolescents. Drawing on this literature, we reflect on the importance of ethically informed, ecologically sensitive clinical practices in relation to ADHD diagnosis and treatment.
Literatur
1.
Conrad P. Identifying hyperactive children: The medicalization of deviant behaviour. Lexington, MA: Lexington Books; 1976.
2.
Conrad P. The medicalization of society: On the transformation of human conditions into treatable disorders. Baltimore, Johns Hopkins UP;2007.
3.
Shrag P, Divoky D. The myth of the hyperactive child and other means of child control. New York: Pantheon;1975.
4.
Barkley R. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain Dev. 2003;25:77–83.PubMedCrossRef
5.
Malacrida C. Medicalization, Ambivalence and Social Control: Mothers’ Descriptions of Educators and ADD/ADHD. Health (London). 2004;8(1):61–80.CrossRef
6.
Horwitz A. Creating mental illness. Chicago: Chicago UP; 2002.
7.
Sonuga-Barke EJ, Schlotz W, Kreppner J. Differentiating developmental trajectories for conduct, emotion and peer problems following early deprivation. Monographs of the Society for Research in Child Development. 2010;75:102–24.PubMedCrossRef
8.
9.
Mayes R, Bagwell C, Erkulwater J. ADHD and the Rise in Stimulant Use Among Children. Harv Rev Psychiatry. 2008;16:151–66.PubMedCrossRef
10.
11.
• Parens E. On good and bad forms of medicalization. Bioethics. 2013;27(1):28–35. An important development in the medicalization debates that moves the concept on from older versions into interesting and useful new territory.PubMedCrossRef
12.
13.
Worthman CM, Protsky PM, Schechter DS, Cummings CA. Formative experiences: The interaction of caregiving, culture and developmental biology. Cambridge, UK: CUP; 2010.CrossRef
14.
Layard R, Dunn J. A Good Childhood. London: Penguin; 2009.
15.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM) – 5. Virginia, USA: American Psychiatric Publishing; 2013.
16.
Centres for Disease Control and Prevention (CDC). Mental health surveillance among children- United States, 2005–2011. Atlanta, GA: US Dept of Health and Human Services; 2013.
17.
Schwarz A, Cohen S. A.D.H.D. Seen in 11% of U.S. Children as Diagnoses Rise. The New York Times March. 2013(31).
18.
Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff. 2007;26:450–7.CrossRef
19.
Cornejo JW, Osio O, Sanchez Y, et al. Prevalence of attention deficit hyperactivity disorder in Columbian children and teenagers. Rev Neurol. 2005;40(12):716–22 [in Spanish].PubMed
20.
Pineda D, Ardila A, Rosselli M, et al. Prevalence of attention—deficit/hyperactivity disorder symptoms in 4–17 year old children in the general population. J Abnorm Child Psychol. 1999;27(6):455–62.PubMedCrossRef
21.
Pino P, Mojarro-Praxedes M. Hyperkinetic D disorders: double-phase epidemiological study of a population from Sevilla. An Psiquiatria. 2001;17(6):265–70 [in Spanish].
22.
Catalá-López F, Peiró S, Ridao M, Sanfélix-Gimeno G, Gènova-Maleras R, Catalá MA. Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry. 2012; doi: 10.​1186/​1471-244X-12-168
23.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.PubMedCrossRef
24.
Polanczyk G, Jensen P. Epidemiological considerations in Attention Deficit Hyperactivity Disorder: A review and update. Child Adolesc Psychiatric Clin N Am. 2008;17:245–60.CrossRef
25.
Gomez R, Harvey J, Quick C, et al. DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry. 1999;40(2):265–74.PubMedCrossRef
26.
Levy F, Hay DC, McStephen M, et al. Attention deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Child Adolesc Psychiatry. 1997;36(6):737–44.CrossRef
27.
28.
29.
• Zuvekas S, Vitiello B. Stimulant medication use among US children: A twelve-year perspective. Am J Psychiatry. 2012;169(2):160–66. A careful longitudinal study showing a slowing in overall rates of stimulant medication use among US children over the twelve year period, but a worrying increase in use among adolescents.PubMedCrossRef
30.
31.
Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry. 2004;184:8–9.PubMedCrossRef
32.
Moffitt TE, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? Am J Psychiatry. 2007;164(6):856–8.PubMedCrossRef
33.
Amaral OB. Psychiatric disorders as social constructs: ADHD as a case in point. Am J Psychiatry. 2007;164:1612–3.PubMedCrossRef
34.
Bass JK, Bolton PA, Murray LK. Do not forget culture when studying mental health. The Lancet. 2007;370(9591):918–9.CrossRef
35.
Watters E. Crazy like us: The globalization of the American psyche. New York: Free Press; 2010.
36.
Kirmayer L. Beyond the ‘new cross-cultural psychiatry’: Cultural biology, discursive psychology and the ironies of globalization. Transcult Psychiatry. 2006;43(1):126.PubMedCrossRef
37.
Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PloS Medicine. 2008;5(5):e106.PubMedCrossRef
38.
Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham and London: Duke University Press; 2012.
39.
40.
41.
42.
43.
44.
Farmer P. An Anthropology of Structural Violence. Curr Anthropol. 2004;45(3).
45.
Canino G, Alegria M. Psychiatric diagnosis- is it universal or relative to culture? J Child Psychol Psychiatry. 2008;49(3):237–50.PubMedCrossRef
46.
Wakefield JC, Pottick KJ, Kirk SA. Should the DSM-IV criteria for conduct disorder consider social context? Am J Psychiatry. 2002;159:380–6.PubMedCrossRef
47.
Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. Attention-Deficit/Hyperactivity Disorder in a Diverse Culture: Do Research and Clinical Findings Support the Notion of a Cultural Construct for the Disorder? Biol Psychiatry. 2005;57:1436–41.PubMedCrossRef
48.
Bronfenbrenner U. The ecology of human development. Camridge, MA: Harvard UP; 1979.
49.
Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Advanced Medical Science. 2009;54:20–6.
50.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMedCrossRef
51.
52.
Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, Modrek S. National Variation of ADHD Diagnostic Prevalence and Medication Use: Health Care Providers and Education Policies. Psychiatr Serv. 2009;60(80).
53.
Getahun G, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent Trends in Childhood Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2013;167(3):282–8.PubMedCrossRef
54.
Froehlich TE, Lamphear BP, Epstein JN, Barbesi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of Attention-Deficit/Hyperactivity Disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857–64.PubMedCrossRef
55.
Zima BT, Bussing R, Tang L, Zhang L, Ettner S, Belin TR, et al. Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care Medicaid program. J Am Acad Child Adolesc Psychiatry. 2010;49(12):1225–37.PubMed
56.
Zito JM, Safer DJ, Devadatta S, Gardner JF, Thomas D, Coombes P, et al. Pediatrics. 2008;121(1):e157–163.PubMedCrossRef
57.
Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S. Racial and Ethnic Disparities in ADHD Diagnosis From Kindergarten to Eighth Grade. Pediatr. 2013; doi: 10.​1542/​peds.​2012-2390
58.
Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spiznagel EL. Prevalence and correcolates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:571–9.PubMedCrossRef
59.
60.
61.
62.
Singh I. Doing their jobs: Mothering with Ritalin in a culture of mother-blame. Soc Sci Med. 2004;59(6):1193–205.PubMedCrossRef
63.
Koro-Ljungberg M, Bussing R. The management of courtesy stigma in the lives of families with teenagers with ADHD. J Fam Issues. 2009;30:1175–200.CrossRef
64.
Frazzetto G, Keenan S, Singh I. Bambini e le droghe: The case of ADHD and Ritalin in Italy. BioSocieties. 2008;2(4):393–412.CrossRef
65.
66.
Singh I. A disorder of anger and aggression: Children's perspectives on Attention Deficit/Hyperactivity Disorder in the UK. Soc Sci Med. 2011;73:889–96.PubMedCrossRef
67.
Bröer C, Heerings M. Neurobiology in public and private discourse: the case of adults with ADHD. Sociol Health & Ill. 2013;35(1):49–65.CrossRef
68.
Filipe AM. Through the looking-glass: a critical review of sociology and medicine towards the diagnosis of ADHD. Configurações. 2011;8:73–86.CrossRef
69.
Edwards C, Howlett E. Putting knowledge to trial: ‘ADHD parents’ and the evaluation of alternative therapeutic regimes. Soc Sci Med. 2013;81:34–41.PubMedCrossRef
70.
71.
Ortega F. The Cerebral Subject and the Challenge of Neurodiversity. BioSocieties. 2009;4:425–45.CrossRef
72.
Behague D. Psychiatry and Politics in Pelotas, Brazil: The Equivocal Quality of Conduct Disorder and Related Diagnoses. Med Anthropol Q. 2009;23(4):455–82.PubMedCrossRef
73.
Wilcox CE, Washburn R, Patel V. Seeking help for attention deficit hyperactivity disorder in developing countries: a study of parental explanatory models in Goa. India Soc Sci Med. 2007;64(8):1600–10.CrossRef
74.
Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM. Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications. Pharmacoepidemiol Drug Saf. 2012;21(4):442–9. doi:10.​1002/​pds.​2264.PubMedCrossRef
75.
Wang PS, Berglund P, Olfson M, Pincus HA. Wells, Kessler RC. Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry. 2005;62(6):603–13.
76.
77.
78.
79.
80.
Green JG, Gruber MJ, Kessler RC, Lin JY, McLaughlin MA, Sampson NA, et al. Diagnostic validity across racial and ethnic groups in the assssment of adolescent DSM-IV disorders. Int J Methods Psychiatr Res. 2012;21(14):311–20.PubMedCrossRef
81.
• Nigg J. Future directions in ADHD etiology research. J Clin Child Adolesc Psychol. 2012;41(4):524–33. Key overview of the importance of specifying environmental and historical contributions to ADHD etiology.PubMedCrossRef
82.
Frank A. The Wounded Storyteller: Body, Illness, and Ethics. Chicago: University of Chicago Press; 2010.
83.
Kleinman A. Rethinking Psychiatry: from cultural category to personal experience. New York: The Free Press; 1988.
84.
Good B. Medicine, Rationality, and Experience: An Anthropological Perspective. Cambridge: Cambridge UP; 1994.
85.
Singh I, Kelleher KJ. Brain enhancement in children. In: Farah M, Chatterjee A, editors. Neuroethics in Practice. Oxford, UK: Oxford University Press; 2013.
86.
Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience & Biobehav Rev. 2010;34(8):1256–66.CrossRef
87.
Hall WD, Lucke JC. The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction. 2010;105(12):2041–3.PubMedCrossRef
88.
Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187–206.PubMedCrossRef
89.
•• Smith MF, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717–41. The most authoritative overview to date of the scientific literature on cognitive enhancement, and a meta-analysis of US prevalence estimates.PubMedCrossRef
90.
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students are students treating themselves for attention problems? J Atten Disord. 2009;13(3):259–70.PubMedCrossRef
91.
• Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2012;64(1):496–505. The first systematic investigation of the important question of how perceptions of cognitive enhancement correlate with objectively measurable outcomes.PubMed
92.
Vrecko S. Just how cognitive is “cognitive enhancement”? On the significance of emotions in university students’ experiences with study drugs. AJOB Neuroscience. 2013;4(1):4–12.PubMedCrossRef
93.
•• Ragan CI, Bard I, Singh I. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology. 2013;64:588–95. doi:10.​1016/​j.​neuropharm.​2012.​06.​016. Authoritative overview of cross-national prevalence estimates in cognitive enhancement; and an assessment of need for policy intervention.PubMedCrossRef
94.
Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt A, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry. 2010;43:1–7.CrossRef
95.
96.
Hansard. HC Deb 4 June 2013, cc1072W-1073W.
97.
98.
Swanson JM, Wigal T, Volkow ND. Contrast of medical and non-medical use of stimulant drugs: Basis for the distinction, and risk of addicition: Comment on Smith and Farah. Psychol Bull. 2011;137(5):742–8.PubMedCrossRef
99.
Rimsza ME, Moses KS. Substance abuse on the college campus. Pediatr Clin North Am. 2005;52(1):307–19.PubMedCrossRef
100.
Friedman RA. The Changing Face of Teenage Drug Abuse - The Trend toward Prescription Drugs. N Engl J Med. 2006;354(14):1448–50.PubMedCrossRef
101.
Schwarz A. Attention-Deficit Drugs Face New Campus Rules. The New York Times. 30 April 2013.
102.
Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction. 2012;107(3):467–77.PubMedCrossRef
103.
Rabiner DL. Stimulant Prescription Cautions: Addressing Misuse. Diversion and Malingering Curr Psychiatry Rep. 2013;15(7):1–8.
104.
105.
Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. Can Med Assoc J. 2001;1658:1039–44.
106.
Garnier-Dykstra LM, Caldeira KM, Vincent KB, O’Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: Four-year trends in exposure opportunity, use, motives, and sources. J Am Coll Health. 2012;60(3):226–34.PubMedCrossRef
107.
McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269–78.PubMedCrossRef
108.
109.
Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics. 2009;15(3):311–41.PubMedCrossRef
110.
Harris J. Enhancing Evolution: The Ethical Case for Making Better People. Princeton University Press; 2007
111.
Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702–5.PubMedCrossRef
112.
Larriviere D, Williams MA, Rizzo M, Bonnie RJ. Responding to requests from adult patients for neuroenhancements Guidance of the Ethics. Law and Humanities Committee Neurology. 2009;73(17):1406–12.
113.
British Medical Association (BMA). Boosting your Brainpower: Ethical Aspects of Cognitive Enhancement. Report, Nov 2007.
114.
115.
Singh I, Kelleher KJ. Neuroenhancement in young people: proposal for research, policy and clinical management. Am J Bioeth Neurosci. 2010;1(1):3–16.
116.
•• Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D. Pediatric neuroenhancement Ethical, legal, social, and neurodevelopmental implications. Neurology. 2013;80(13):1251–60. First public statement by a professional group (American Academy of Neurology) on pediatric cognitive enhancement.PubMedCrossRef
117.
Sonuga-Barke EJ, Koerting J, Smith E, McCann DS, Thompson M. Early detection and intervention for attention deficit hyperactivity disorder. Expert Review of Neurotherapeutics. 2011;11(4):557–63.PubMedCrossRef
118.
Singh I, Sinnott-Armstrong W, Savulescu J. (in press). Bioprediction, Biomarkers, and Bad Behavior: Scientific, Legal, and Ethical Challenges. Oxford UP.
119.
Singh I, Rose N. Biomarkers in psychiatry: Promises and perils in the real world. Nature. 2009;460(7252):202–7.PubMedCrossRef
Metadaten
Titel
Globalization and Cognitive Enhancement: Emerging Social and Ethical Challenges for ADHD Clinicians
verfasst von
Ilina Singh
Angela M. Filipe
Imre Bard
Meredith Bergey
Lauren Baker
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 9/2013
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-013-0385-0

Weitere Artikel der Ausgabe 9/2013

Current Psychiatry Reports 9/2013 Zur Ausgabe

Mood Disorders (SM Strakowski, Section Editor)

Integrative Medicine for Treating Depression: An Update on the Latest Evidence

Geriatric Disorders (H Lavretsky, Section Editor)

Depression in Cognitive Impairment

Sleep Disorders (RM Benca, Section Editor)

The Link Between Suicide and Insomnia: Theoretical Mechanisms

Mood Disorders (SM Strakowski, Section Editor)

Is Depression Simply a Nonspecific Response to Brain Injury?

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Psychopharmacology in Psycho-oncology

Sleep Disorders (RM Benca, Section Editor)

Ketamine, Sleep, and Depression: Current Status and New Questions

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise